FOR IMMEDIATE RELEASE: Lewis Holds Healthcare Roundtable in Luverne
LUVERNE, Minn. — U.S. Senate Candidate Jason Lewis continued his push for better and more affordable healthcare Wednesday by holding a rural healthcare roundtable at the Sanford Medical facilities in Luverne, Minnesota.
“The Democrats’ radical proposals are an admission that Obamacare is not working as intended. In fact, while the CBO had predicted over 25 million enrollees on exchanges like MNsure by now, the latest federal numbers show just 11 million can afford the skyrocketing costs of health care. It’s time for real reform,” Lewis said.
“My common sense reforms to lower insurance premiums and provide more options with private, portable plans, including maintaining popular employer-based benefits instead of removing 160 million Americans from their existing group plans. This stands in stark contrast to Senator Tina Smith’s support for, at most reasonable estimates, a $32 trillion ‘Medicare for All’ socialist scheme that would upend our current health insurance system, abolish private plans, and eliminate Medicare for seniors as we know it,” Lewis added.
During the roundtable at Sanford Medical, Lewis unveiled some of the details of his plan for improving healthcare access for all Minnesotans, including:
—allow pre-tax dollars for all health care expenses on the individual market, finally equaling the tax treatment with employer-based coverage
—continue the Trump administration’s reform efforts by making small business ‘association pools’ and inexpensive shorter-term plans permanent
—lower the cost of delivery through new technologies, such as Sanford’s ‘telestroke’ program, so rural physicians can quickly diagnose patients via video
—end the spiraling premium costs for preexisting conditions by establishing invisible pools for the hard-to-insure
—require pharmaceutical benefits managers’ rebates to be passed on to consumers, and allow treatments for chronic conditions (such as insulin, inhalers) to be covered as preventative —encourage quicker development of generics and biosimilars by ending the pharmaceutical practice of ‘evergreening’ expiring patents